Answers are grounded in this paper and cite their sources.
Previously resistance of members of Enterobacteriaceae family to carbapenem was defined as being insensitive to doripenem, meropenem, or imipenem, and also being resistant to all third-generation cephalosporins. However, in November 2015, ertapenem resistance was added to the list, and being resistant to all cephalosporins was removed from the definition (7). The CRE control guide of the Centers for Disease Control and Prevention (CDC) defined the CRE resistance as being resistant to any carbapenem antibiotic (i.e., minimum inhibitory concentrations of 4 mg/mL for doripenem, meropenem, or imipenem OR 2 mg/ml for ertapenem) or documentation of carbapenemase production. Further, the bacteria that are intrinsically resistant to imipenem (i.e., Morganella morganii, Proteus spp., Providencia spp.) should be resistant to non-imipenem carbapenems, and one of the polymerase chain reaction, modified Hodge test, Carba NP, or metallo-b-lactamase tests should be used to determine carbapenemase production (7). The breakpoints for carbapenem resistance according to the European Committee on Antimicrobial Susceptibility Testing and the Clinical & Laboratory Standards Institute (CLSI) are presented in Table
No takes yet. Share an insight, caveat, or question.
Fatma Eser (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: